Adjuvant Treatment of Fully Resected Stage III Colon Cancer With FOLFOX-4 Versus FOLFOX-4 Plus Cetuximab

Trial Profile

Adjuvant Treatment of Fully Resected Stage III Colon Cancer With FOLFOX-4 Versus FOLFOX-4 Plus Cetuximab

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Cetuximab (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
  • Indications Adenocarcinoma; Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms PETACC-8
  • Most Recent Events

    • 06 Jun 2017 Results of clinical utility of colon cancer molecular subtypes presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 02 Jun 2017 Results (n=1869) assessing prognostic value of primary location and its relationship to MSI, RAS and BRAF mutational status, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 25 May 2017 Data from this trial will be presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO), as reported in a NanoString Technologies media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top